Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension

Keyphrases

• Low Blood Pressure 100%
• Plasminogen Activation 100%
• Amiloride 100%
• Resistant Hypertension 100%
• Plasminogen 50%
• Type 2 Diabetes Mellitus (T2DM) 37%
• Plasmin 37%
• Microalbuminuria 25%
• Urokinase-type Plasminogen Activator 25%
• Epithelial Sodium Channel (ENaC) 25%
• Blood Pressure Control 12%
• Systolic Blood Pressure 12%
• Diastolic Blood Pressure 12%
• Adverse Events 12%
• Hyperactivity 12%
• Intervention Studies 12%
• Type 2 Diabetic Patients 12%
• Blood Pressure 12%
• Hyperkalemia 12%
• Diuretics 12%
• Antihypertensive Treatment 12%
• Albuminuria 12%
• Urinary Albumin Excretion 12%
• Albumin-to-creatinine Ratio 12%
• Renin-angiotensin-aldosterone System 12%
• Proteinuria 12%
• Daytime Blood Pressure 12%
• Ambulatory Blood Pressure Monitoring 12%
• Collecting Duct 12%
• Urokinase 12%
• Urine Analysis 12%
• Add-on Medications 12%
• Tubular System 12%
• ENaC Inhibitors 12%
• Glomerular Filtration Barrier 12%

Neuroscience

• Plasminogen 100%
• Amiloride 100%
• Fibrinolysin 50%
• Epithelial Sodium Channel 50%
• Diabetes Mellitus 37%
• Urokinase 37%
• Hyperactivity 12%
• Angiotensin 12%
• Renin 12%
• Creatinine 12%
• Aldosterone 12%
• Diuretic 12%
• Estropipate 12%